Nuvation Bio SIGMA (AB-218-G203): Safusidenib Phase 3 study in IDH1-mutant glioma
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or…
- Investigator
- Ashley Ghiaseddin
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
OPTIMUS PRIME - Laser Ablation Surgery and Pembrolizumab for Recurrent Glioblastoma
In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive…
- Investigator
- Ashley Ghiaseddin
- Status
- Accepting Candidates
- Ages
- 18 Years - 90 Years
- Sexes
- All